Mentions
Extended reach
Total likes
Video views
AI synopsis
The collective sentiment is overwhelmingly positive, highlighting the extraordinary outcome where 12 out of 12 patients with advanced rectal cancer achieved complete remission without surgery or chemo. Words like 'game-changing,' 'incredible efficacy,' and 'paradigm shift' demonstrate excitement and recognition of potential medical breakthroughs, driven by the clear reporting of 100% success among study participants.
Most discussions celebrate the study's remarkable results, emphasizing that all patients experienced complete remission, indicating strong consensus.
The persistent attention and detailed commentary reflect a high level of curiosity and engagement from the community.
Many comments analyze the significance, potential for changing treatment norms, and implications for future cancer therapy, showing deep involvement.
Several discussions label this as a paradigm-shifting breakthrough with potentially transformative effects on cancer treatment practices.
2/ En primer lugar es de agradecer que, para variar, el periodista haya enlazado el artículo del que habla. Es este de aquí, aunque or desgracia se encuentra tras un paywall y todavía no está en sci-hub: https://t.co/PClbwP8UXO
Media Sensation on Rectal Cancers vanishing with Immuno drug Dostarlimab without Surgery/Radiatn/Chemo Its a signal getting brighter but 1 among many wins of #CancerResearch that needs unlimited Public support & resources/ facilitation from Govt/Charities https://t.co/sz0DpWBC2v https://t.co/n53DDFJm6i
PD-1 Blockade in Mismatch Repair–Deficient, Locally Advanced Rectal Cancer. COMPLETE RESPOSNES in 12/12 patients. Paradigm changing study @NEJM @AndreaCercek @Dr_R_Kurzrock https://t.co/oLZQt04a3O https://t.co/kzUcb9aP5q
SOURCE (1) Andrea Cerceck Regarding clinical trial research paper - "PD-1 Blockade in Mismatch Repair–Deficient, Locally Advanced Rectal Cancer" "Such incredible efficacy, with really almost no toxicity" https://t.co/YlItz6TYaz
Peer-reviewed Reference: Cercek A, et al. “PD-1 Blockade in Mismatch Repair–Deficient, Locally Advanced Rectal Cancer.” New England Journal of Medicine.
دراسة طبية أوردت نتائج مذهلة لعلاج سرطان المستقيم باستخدام الأجسام المضادة وحيدة النسيلة (Monoclonal Antibodies)، سابقة غير مسبوقة في علاج السرطان. •عنوان الدراسة: PD-1 Blockade in Mismatch Repair–Deficient, Locally Advanced Rectal Cancer •الجهة التي أجرت الدراسة: مركز https://t.co/4zOmKbxh7O
Neoadjuvant chemotherapy and radiation are standard treatments for locally advanced rectal cancer, particularly in cases with mismatch repair deficiency, which may respond well to PD-1 blockade therapy. A phase 2 study…
Emerging evidence indicates that fasting may enhance cancer treatment by creating an environment that hinders cancer cell survival and growth. This video explores the potential benefits of integrating prolonged fasting…
Article httpswwwnejmorgdoifull101056NEJMoa2201445. A phase 2 study using dostarlimab, an anti-PD-1 antibody, shows complete tumor response in mismatch repair-deficient rectal cancer patients, potentially allowing some…
Locally advanced rectal cancer often involves chemotherapy, radiotherapy, and surgery. In a recent study, PD-1 inhibitor dostarlimab was used for 6 months in mismatch repair deficient tumors, leading to complete…
The video discusses a clinical trial where dostarlimab, an anti-PD-1 therapy, was used to treat 12 patients with mismatch repair-deficient rectal cancer, resulting in complete tumor disappearance and no significant…
This video discusses a phase 2 study evaluating dostarlimab, an anti-PD-1 therapy, showing a complete tumor response in all patients with mismatch repair-deficient rectal cancer, potentially reducing the need for…
RT @ShiningScience: Peer-reviewed Reference: Cercek A, et al. “PD-1 Blockade in Mismatch Repair–Deficient, Locally Advanced Rectal Cancer.…
RT @ShiningScience: Peer-reviewed Reference: Cercek A, et al. “PD-1 Blockade in Mismatch Repair–Deficient, Locally Advanced Rectal Cancer.…
RT @ShiningScience: Peer-reviewed Reference: Cercek A, et al. “PD-1 Blockade in Mismatch Repair–Deficient, Locally Advanced Rectal Cancer.…
RT @ShiningScience: Peer-reviewed Reference: Cercek A, et al. “PD-1 Blockade in Mismatch Repair–Deficient, Locally Advanced Rectal Cancer.…
Peer-reviewed Reference: Cercek A, et al. “PD-1 Blockade in Mismatch Repair–Deficient, Locally Advanced Rectal Cancer.” New England Journal of Medicine.
@edivdealed Cercek, A., Lumish, M., Sinopoli, J., Weiss, J., Yaeger, R., Cercek, A., … Diaz, L. A. Jr. (2022). PD-1 Blockade in Mismatch Repair–Deficient, Locally Advanced Rectal Cancer. The New England Journal of Medicine (NEJM), 386(25), 2363–2376. https://t.co/2F5M8RL4Ut
@denisrancourt At the turn of the 1980s, Michel Foucault coined an expression that enjoyed dazzling success : the notion of "biopower." also immunotherapy might be useful DOI: 10.1056/NEJMoa2201445
Fact #84: A small clinical trial used an immunotherapy drug that led to a 100% remission rate in rectal cancer patients. 12 patients were treated and after 6 months cancer was undetectable in each one. https://t.co/WYKEpxy9ST
@VigilantFox https://t.co/bqkQNgLxrs
RT @AndreaCercek: Very proud of our study published in @NEJM. 100% clinical complete response with dostarlimab alone in mismatch repair-def…
RT @AndreaCercek: Very proud of our study published in @NEJM. 100% clinical complete response with dostarlimab alone in mismatch repair-def…
@DefiantLs https://t.co/jQg3zmdGF4
RT @AndreaCercek: Very proud of our study published in @NEJM. 100% clinical complete response with dostarlimab alone in mismatch repair-def…
@SPOTNEWSonIG Have you seen this Spot? Just checking. Just came out. https://t.co/pwu5CgVkUy
RT @Robertonuzzoam: NEW ENGLAND JOURNAL MEDICINE (PDF in italiano): https://t.co/6VTK0AlKpS NEW ENGLAND JOURNAL MEDICINE 2022 (originale):…
Notizia ORIGINALE (2022):* https://t.co/XEXKKBZjYR *Studio scientifico in italiano (pdf):* https://t.co/tfh2IRLO6f *Studio scientifico originale:* https://t.co/7ielz6OQFy
RT @NedaaAlkhamis: دراسة طبية أوردت نتائج مذهلة لعلاج سرطان المستقيم باستخدام الأجسام المضادة وحيدة النسيلة (Monoclonal Antibodies)، سابقة…
RT @Robertonuzzoam: NEW ENGLAND JOURNAL MEDICINE (PDF in italiano): https://t.co/6VTK0AlKpS NEW ENGLAND JOURNAL MEDICINE 2022 (originale):…
RT @drCParks1: The original paper. https://t.co/ftnr06q489
RT @Humanspective: SOURCE research paper (1) https://t.co/SAKXP1oiY0 https://t.co/oBq3VJXASB
RT @Humanspective: SOURCE (1) Andrea Cerceck Regarding clinical trial research paper - "PD-1 Blockade in Mismatch Repair–Deficient, Locally…
RT @Robertonuzzoam: NEW ENGLAND JOURNAL MEDICINE (PDF in italiano): https://t.co/6VTK0AlKpS NEW ENGLAND JOURNAL MEDICINE 2022 (originale):…
RT @Robertonuzzoam: NEW ENGLAND JOURNAL MEDICINE (PDF in italiano): https://t.co/6VTK0AlKpS NEW ENGLAND JOURNAL MEDICINE 2022 (originale):…
NEW ENGLAND JOURNAL MEDICINE (PDF in italiano): https://t.co/6VTK0AlKpS NEW ENGLAND JOURNAL MEDICINE 2022 (originale): https://t.co/pE0uuMMEHN SCIENCE DIRECT 2024 (pdf in italiano): https://t.co/St8NXPjfig SCIENCE DIRECT (originale): https://t.co/lWOX0TW2Pz https://t.co/LGLp7oAe7c
The original paper. https://t.co/ftnr06q489
Studie: https://t.co/VUhGe6jZOX
Study: https://t.co/krUINxLvJX https://t.co/uyum4NBX4u
RT @NedaaAlkhamis: دراسة طبية أوردت نتائج مذهلة لعلاج سرطان المستقيم باستخدام الأجسام المضادة وحيدة النسيلة (Monoclonal Antibodies)، سابقة…
RT @Humanspective: SOURCE (1) Andrea Cerceck Regarding clinical trial research paper - "PD-1 Blockade in Mismatch Repair–Deficient, Locally…
RT @NedaaAlkhamis: دراسة طبية أوردت نتائج مذهلة لعلاج سرطان المستقيم باستخدام الأجسام المضادة وحيدة النسيلة (Monoclonal Antibodies)، سابقة…
@MichaiMorin @TheProjectUnity Until then you can read the origin study here: https://t.co/uLSvA6vgkb (I dont get how one can skip that simple research to provide the paper in his post about it, but I know this is how social media works
RT @Humanspective: SOURCE research paper (1) https://t.co/SAKXP1oiY0 https://t.co/oBq3VJXASB
RT @Humanspective: SOURCE (1) Andrea Cerceck Regarding clinical trial research paper - "PD-1 Blockade in Mismatch Repair–Deficient, Locally…
RT @AndreaCercek: Very proud of our study published in @NEJM. 100% clinical complete response with dostarlimab alone in mismatch repair-def…
RT @NedaaAlkhamis: دراسة طبية أوردت نتائج مذهلة لعلاج سرطان المستقيم باستخدام الأجسام المضادة وحيدة النسيلة (Monoclonal Antibodies)، سابقة…
RT @Humanspective: SOURCE research paper (1) https://t.co/SAKXP1oiY0 https://t.co/oBq3VJXASB
RT @Humanspective: SOURCE (1) Andrea Cerceck Regarding clinical trial research paper - "PD-1 Blockade in Mismatch Repair–Deficient, Locally…
Important to note that this all happened before RFK Jr was at the helm of HHS. The original study was published in June 2022: https://t.co/7XLKNYPWVj And yes, there was government funding involved.
RT @Humanspective: SOURCE (1) Andrea Cerceck Regarding clinical trial research paper - "PD-1 Blockade in Mismatch Repair–Deficient, Locally…
@VigilantFox https://t.co/dSAi5V8Gdc
RT @Humanspective: SOURCE research paper (1) https://t.co/SAKXP1oiY0 https://t.co/oBq3VJXASB
RT @Humanspective: SOURCE (1) Andrea Cerceck Regarding clinical trial research paper - "PD-1 Blockade in Mismatch Repair–Deficient, Locally…
RT @AndreaCercek: Very proud of our study published in @NEJM. 100% clinical complete response with dostarlimab alone in mismatch repair-def…
RT @NedaaAlkhamis: دراسة طبية أوردت نتائج مذهلة لعلاج سرطان المستقيم باستخدام الأجسام المضادة وحيدة النسيلة (Monoclonal Antibodies)، سابقة…
دراسة طبية أوردت نتائج مذهلة لعلاج سرطان المستقيم باستخدام الأجسام المضادة وحيدة النسيلة (Monoclonal Antibodies)، سابقة غير مسبوقة في علاج السرطان. •عنوان الدراسة: PD-1 Blockade in Mismatch Repair–Deficient, Locally Advanced Rectal Cancer •الجهة التي أجرت الدراسة: مركز https://t.co/4zOmKbxh7O
@SigrunHring @VigilantFox Date on the paper is 2022. https://t.co/i7v7BY4pl1
RT @Humanspective: SOURCE (1) Andrea Cerceck Regarding clinical trial research paper - "PD-1 Blockade in Mismatch Repair–Deficient, Locally…
@serviceguynj @VigilantFox @RobertKennedyJr The original study was published in June 2022: https://t.co/7XLKNYPWVj Since then, additional work has been done and the treatment was given the green light late last year: https://t.co/B6EfIncWdG This was before RFK Jr got involved. https://t.co/7Gjf83G1ol
@STLCards42069 @bimald @VigilantFox The study was first published in June 2022, and was funded in part by the NIH: https://t.co/7XLKNYPWVj https://t.co/O0w7bHO3AL
RT @Humanspective: SOURCE research paper (1) https://t.co/SAKXP1oiY0 https://t.co/oBq3VJXASB
@VigilantFox https://t.co/CZWQJ5f8Dr
RT @Humanspective: SOURCE (1) Andrea Cerceck Regarding clinical trial research paper - "PD-1 Blockade in Mismatch Repair–Deficient, Locally…
Miejmy nadzieję, że dla pacjentów z rakiem jelita grubego (odbytu) związanym z mutacjami genów naprawy uszkodzeń DNA, ta terapia okaże się tak skuteczna jak imatinib w PBS. Ale to nie są najczęstsze raki jelita grubego. https://t.co/HYmyLuARnO
@sujanapriya Based on MSKCC dostarlimab study. Update presented at ASCO 2024 I believe w 40+ patients, still 100% CR. Azur 1 trial completed not yet reported. All not randomized trials but most would not have equipoise at this pt for RCT. https://t.co/t9OAT4lpHk
@Pr_Chabriere_E exemple; cet article montre la disparition sous traitement d'une forme particulière de tumeur rectale chez 12 patients sur 12. le NEJM le publie à juste titre en 2022 https://t.co/a7grKIhI1G
RT @AdelinaSfishta: Haberde 2 link var onları buraya koydum.. ABD ilgili birimi onaylamış, satışa konmuş.. https://t.co/tt21V9VHMF https://…
Dostarlimab (GSK), एक एंटी-PD1 एंटीबॉडी को स्थानीय रूप से उन्नत dMMR/MSI-H रेक्टल कैंसर के लिए दिसंबर 2024 में ब्रेकथ्रू थेरेपी पदनाम से सम्मानित किया गया था। मूल शोध लेख एनईजेएम, 2022 (https://t.co/tAnZorpcYF) में प्रकाशित हुआ।
Dostarlimab (GSK), an anti-PD1 antibody was awarded breakthrough therapy designation in Dec 2024 for locally advanced dMMR/MSI-H rectal cancers. Original research article published in NEJM, 2022 (https://t.co/tAnZorpcYF).
RT @AdelinaSfishta: Haberde 2 link var onları buraya koydum.. ABD ilgili birimi onaylamış, satışa konmuş.. https://t.co/tt21V9VHMF https://…
RT @AdelinaSfishta: Haberde 2 link var onları buraya koydum.. ABD ilgili birimi onaylamış, satışa konmuş.. https://t.co/tt21V9VHMF https://…
RT @AdelinaSfishta: Haberde 2 link var onları buraya koydum.. ABD ilgili birimi onaylamış, satışa konmuş.. https://t.co/tt21V9VHMF https://…
RT @AdelinaSfishta: Haberde 2 link var onları buraya koydum.. ABD ilgili birimi onaylamış, satışa konmuş.. https://t.co/tt21V9VHMF https://…
RT @AdelinaSfishta: Haberde 2 link var onları buraya koydum.. ABD ilgili birimi onaylamış, satışa konmuş.. https://t.co/tt21V9VHMF https://…
RT @AdelinaSfishta: Haberde 2 link var onları buraya koydum.. ABD ilgili birimi onaylamış, satışa konmuş.. https://t.co/tt21V9VHMF https://…
RT @AdelinaSfishta: Haberde 2 link var onları buraya koydum.. ABD ilgili birimi onaylamış, satışa konmuş.. https://t.co/tt21V9VHMF https://…
RT @AdelinaSfishta: Haberde 2 link var onları buraya koydum.. ABD ilgili birimi onaylamış, satışa konmuş.. https://t.co/tt21V9VHMF https://…
RT @AdelinaSfishta: Haberde 2 link var onları buraya koydum.. ABD ilgili birimi onaylamış, satışa konmuş.. https://t.co/tt21V9VHMF https://…
RT @AdelinaSfishta: Haberde 2 link var onları buraya koydum.. ABD ilgili birimi onaylamış, satışa konmuş.. https://t.co/tt21V9VHMF https://…
RT @AdelinaSfishta: Haberde 2 link var onları buraya koydum.. ABD ilgili birimi onaylamış, satışa konmuş.. https://t.co/tt21V9VHMF https://…
RT @AdelinaSfishta: Haberde 2 link var onları buraya koydum.. ABD ilgili birimi onaylamış, satışa konmuş.. https://t.co/tt21V9VHMF https://…
RT @AdelinaSfishta: Haberde 2 link var onları buraya koydum.. ABD ilgili birimi onaylamış, satışa konmuş.. https://t.co/tt21V9VHMF https://…
RT @AdelinaSfishta: Haberde 2 link var onları buraya koydum.. ABD ilgili birimi onaylamış, satışa konmuş.. https://t.co/tt21V9VHMF https://…
RT @AdelinaSfishta: Haberde 2 link var onları buraya koydum.. ABD ilgili birimi onaylamış, satışa konmuş.. https://t.co/tt21V9VHMF https://…
RT @AdelinaSfishta: Haberde 2 link var onları buraya koydum.. ABD ilgili birimi onaylamış, satışa konmuş.. https://t.co/tt21V9VHMF https://…
RT @AdelinaSfishta: Haberde 2 link var onları buraya koydum.. ABD ilgili birimi onaylamış, satışa konmuş.. https://t.co/tt21V9VHMF https://…
RT @AdelinaSfishta: Haberde 2 link var onları buraya koydum.. ABD ilgili birimi onaylamış, satışa konmuş.. https://t.co/tt21V9VHMF https://…
RT @AdelinaSfishta: Haberde 2 link var onları buraya koydum.. ABD ilgili birimi onaylamış, satışa konmuş.. https://t.co/tt21V9VHMF https://…
RT @AdelinaSfishta: Haberde 2 link var onları buraya koydum.. ABD ilgili birimi onaylamış, satışa konmuş.. https://t.co/tt21V9VHMF https://…
RT @AdelinaSfishta: Haberde 2 link var onları buraya koydum.. ABD ilgili birimi onaylamış, satışa konmuş.. https://t.co/tt21V9VHMF https://…
RT @AdelinaSfishta: Haberde 2 link var onları buraya koydum.. ABD ilgili birimi onaylamış, satışa konmuş.. https://t.co/tt21V9VHMF https://…
@AdelinaSfishta Orjinal makale: https://t.co/rhHlOgHinW
RT @AdelinaSfishta: Haberde 2 link var onları buraya koydum.. ABD ilgili birimi onaylamış, satışa konmuş.. https://t.co/tt21V9VHMF https://…
RT @AdelinaSfishta: Haberde 2 link var onları buraya koydum.. ABD ilgili birimi onaylamış, satışa konmuş.. https://t.co/tt21V9VHMF https://…
RT @AdelinaSfishta: Haberde 2 link var onları buraya koydum.. ABD ilgili birimi onaylamış, satışa konmuş.. https://t.co/tt21V9VHMF https://…
RT @AdelinaSfishta: Haberde 2 link var onları buraya koydum.. ABD ilgili birimi onaylamış, satışa konmuş.. https://t.co/tt21V9VHMF https://…
RT @AdelinaSfishta: Haberde 2 link var onları buraya koydum.. ABD ilgili birimi onaylamış, satışa konmuş.. https://t.co/tt21V9VHMF https://…
RT @AdelinaSfishta: Haberde 2 link var onları buraya koydum.. ABD ilgili birimi onaylamış, satışa konmuş.. https://t.co/tt21V9VHMF https://…
RT @AdelinaSfishta: Haberde 2 link var onları buraya koydum.. ABD ilgili birimi onaylamış, satışa konmuş.. https://t.co/tt21V9VHMF https://…
RT @AdelinaSfishta: Haberde 2 link var onları buraya koydum.. ABD ilgili birimi onaylamış, satışa konmuş.. https://t.co/tt21V9VHMF https://…
RT @AdelinaSfishta: Haberde 2 link var onları buraya koydum.. ABD ilgili birimi onaylamış, satışa konmuş.. https://t.co/tt21V9VHMF https://…
RT @AdelinaSfishta: Haberde 2 link var onları buraya koydum.. ABD ilgili birimi onaylamış, satışa konmuş.. https://t.co/tt21V9VHMF https://…
RT @AdelinaSfishta: Haberde 2 link var onları buraya koydum.. ABD ilgili birimi onaylamış, satışa konmuş.. https://t.co/tt21V9VHMF https://…
RT @ilyassahinMD: T:
RT @AdelinaSfishta: Haberde 2 link var onları buraya koydum.. ABD ilgili birimi onaylamış, satışa konmuş.. https://t.co/tt21V9VHMF https://…
RT @AdelinaSfishta: Haberde 2 link var onları buraya koydum.. ABD ilgili birimi onaylamış, satışa konmuş.. https://t.co/tt21V9VHMF https://…
RT @AdelinaSfishta: Haberde 2 link var onları buraya koydum.. ABD ilgili birimi onaylamış, satışa konmuş.. https://t.co/tt21V9VHMF https://…
RT @AdelinaSfishta: Haberde 2 link var onları buraya koydum.. ABD ilgili birimi onaylamış, satışa konmuş.. https://t.co/tt21V9VHMF https://…
RT @AdelinaSfishta: Haberde 2 link var onları buraya koydum.. ABD ilgili birimi onaylamış, satışa konmuş.. https://t.co/tt21V9VHMF https://…
RT @AdelinaSfishta: Haberde 2 link var onları buraya koydum.. ABD ilgili birimi onaylamış, satışa konmuş.. https://t.co/tt21V9VHMF https://…
RT @AdelinaSfishta: Haberde 2 link var onları buraya koydum.. ABD ilgili birimi onaylamış, satışa konmuş.. https://t.co/tt21V9VHMF https://…
RT @AdelinaSfishta: Haberde 2 link var onları buraya koydum.. ABD ilgili birimi onaylamış, satışa konmuş.. https://t.co/tt21V9VHMF https://…
RT @AdelinaSfishta: Haberde 2 link var onları buraya koydum.. ABD ilgili birimi onaylamış, satışa konmuş.. https://t.co/tt21V9VHMF https://…
RT @AdelinaSfishta: Haberde 2 link var onları buraya koydum.. ABD ilgili birimi onaylamış, satışa konmuş.. https://t.co/tt21V9VHMF https://…
RT @AdelinaSfishta: Haberde 2 link var onları buraya koydum.. ABD ilgili birimi onaylamış, satışa konmuş.. https://t.co/tt21V9VHMF https://…
RT @AdelinaSfishta: Haberde 2 link var onları buraya koydum.. ABD ilgili birimi onaylamış, satışa konmuş.. https://t.co/tt21V9VHMF https://…
RT @AdelinaSfishta: Haberde 2 link var onları buraya koydum.. ABD ilgili birimi onaylamış, satışa konmuş.. https://t.co/tt21V9VHMF https://…
RT @AdelinaSfishta: Haberde 2 link var onları buraya koydum.. ABD ilgili birimi onaylamış, satışa konmuş.. https://t.co/tt21V9VHMF https://…
RT @AdelinaSfishta: Haberde 2 link var onları buraya koydum.. ABD ilgili birimi onaylamış, satışa konmuş.. https://t.co/tt21V9VHMF https://…
RT @AdelinaSfishta: Haberde 2 link var onları buraya koydum.. ABD ilgili birimi onaylamış, satışa konmuş.. https://t.co/tt21V9VHMF https://…
RT @AdelinaSfishta: Haberde 2 link var onları buraya koydum.. ABD ilgili birimi onaylamış, satışa konmuş.. https://t.co/tt21V9VHMF https://…
RT @AdelinaSfishta: Haberde 2 link var onları buraya koydum.. ABD ilgili birimi onaylamış, satışa konmuş.. https://t.co/tt21V9VHMF https://…
RT @AdelinaSfishta: Haberde 2 link var onları buraya koydum.. ABD ilgili birimi onaylamış, satışa konmuş.. https://t.co/tt21V9VHMF https://…
RT @DrGunerSonmez: Küçük bir araştırma ama şimdiye kadar duyulmamış muhteşem bir sonuç; •Kolorektal (kalın bağırsak-makat) kanseri olan 12…
RT @AdelinaSfishta: Haberde 2 link var onları buraya koydum.. ABD ilgili birimi onaylamış, satışa konmuş.. https://t.co/tt21V9VHMF https://…
RT @AdelinaSfishta: Haberde 2 link var onları buraya koydum.. ABD ilgili birimi onaylamış, satışa konmuş.. https://t.co/tt21V9VHMF https://…
RT @AdelinaSfishta: Haberde 2 link var onları buraya koydum.. ABD ilgili birimi onaylamış, satışa konmuş.. https://t.co/tt21V9VHMF https://…
RT @AdelinaSfishta: Haberde 2 link var onları buraya koydum.. ABD ilgili birimi onaylamış, satışa konmuş.. https://t.co/tt21V9VHMF https://…
RT @AdelinaSfishta: Haberde 2 link var onları buraya koydum.. ABD ilgili birimi onaylamış, satışa konmuş.. https://t.co/tt21V9VHMF https://…
RT @AdelinaSfishta: Haberde 2 link var onları buraya koydum.. ABD ilgili birimi onaylamış, satışa konmuş.. https://t.co/tt21V9VHMF https://…
RT @AdelinaSfishta: Haberde 2 link var onları buraya koydum.. ABD ilgili birimi onaylamış, satışa konmuş.. https://t.co/tt21V9VHMF https://…
RT @drkaanyl: Yeni bir çalışmada: Rektal kanserde bir tek immunoterapi ilacı ile yüzde yüz başarı elde edildi. Cerrahi yok, kemoterapi yok,…
毎年約 46,220 人が直腸がんと診断されており、そのうち最大 10% が 局所進行性dMMR/MSI-H 直腸がんです。https://t.co/NBF7eaz8Js
PD-1 Blockade in Mismatch Repair–Deficient, Locally Advanced Rectal Cancer | New England Journal of Medicine https://t.co/6IEH5QuoOD https://t.co/NIoZRoiP2P
@Marzouk_Khawaga موضوع ال microbiome ده معقد جدا أنا كنت بقرأ في بيبر (PD-1 Blockade in Mismatch Repair–Deficient, Locally) Advanced Rectal Cancer) وكانت بتقول إن ممكن يكون سبب استجابة النوع ده من الورم للعلاج بنسبة كبيرة عن غيره هو تأثير ال gut microbiome https://t.co/Wy1Yuh8HXS
RT @Humanspective: SOURCE (1) Andrea Cerceck Regarding clinical trial research paper - "PD-1 Blockade in Mismatch Repair–Deficient, Locally…
RT @Humanspective: SOURCE (1) Andrea Cerceck Regarding clinical trial research paper - "PD-1 Blockade in Mismatch Repair–Deficient, Locally…
RT @Humanspective: SOURCE (1) Andrea Cerceck Regarding clinical trial research paper - "PD-1 Blockade in Mismatch Repair–Deficient, Locally…
RT @Humanspective: SOURCE (1) Andrea Cerceck Regarding clinical trial research paper - "PD-1 Blockade in Mismatch Repair–Deficient, Locally…
RT @Humanspective: SOURCE (1) Andrea Cerceck Regarding clinical trial research paper - "PD-1 Blockade in Mismatch Repair–Deficient, Locally…
RT @Humanspective: SOURCE (1) Andrea Cerceck Regarding clinical trial research paper - "PD-1 Blockade in Mismatch Repair–Deficient, Locally…
RT @Humanspective: SOURCE (1) Andrea Cerceck Regarding clinical trial research paper - "PD-1 Blockade in Mismatch Repair–Deficient, Locally…
This will not help with the quadrennial pain-in-the-ass of election cycles. ‘Unprecedented’, ‘Remarkable’: Cancer Study Leaves Every Patient Cancer-Free https://t.co/AEStmcfHCQ PD-1 Blockade in Mismatch Repair–Deficient, Locally Advanced Rectal Cancer https://t.co/plZMc5WNOr
RT @Humanspective: SOURCE (1) Andrea Cerceck Regarding clinical trial research paper - "PD-1 Blockade in Mismatch Repair–Deficient, Locally…
SOURCE (1) Andrea Cerceck Regarding clinical trial research paper - "PD-1 Blockade in Mismatch Repair–Deficient, Locally Advanced Rectal Cancer" "Such incredible efficacy, with really almost no toxicity" https://t.co/YlItz6TYaz
@HartvNL Kunt de informatie mogelijk doorgeven? https://t.co/ZgQi7ueuTe New England Journal of Medicine PD-1 blockade in mismatch Repair-Deficient, Locally Advanced Rectal Cancer.
@lmschrijver Ik hoop dat u dit nog onder ogen komt. https://t.co/ZgQi7ueuTe "New England of Medicine PD-1 Blockade in mismatch repair-deficient, locally advanced rectal cancer.
This looks promising @DrJohnCampbell3 PD-1 Blockade in Mismatch Repair–Deficient, Locally Advanced Rectal Cancer | New England Journal of Medicine https://t.co/Y1i8pm87p7
PD-1 Blockade in Mismatch Repair–Deficient, Locally Advanced Rectal Cancer | New England Journal of Medicine https://t.co/eNQPNvA9ln
@brian_rini @TresUramigas @Uromigos @neerajaiims @TiansterZhang @HHammersMD @tompowles1 @montypal Older (2020, ICIs move so fast!) review but concepts remain the same! https://t.co/O8fwsaozVQ benefit is seen in non melanoma tumors as well! https://t.co/w9kODUyxIM a trial in RCC is a must!
DOSTARLIMAB anti-PD-1 Monoclonal antibody phase 2 study in which single-agent dostarlimab, an anti–PD-1 monoclonal antibody PD-1 Blockade in Mismatch Repair–Deficient, Locally Advanced Rectal Cancer https://t.co/sGcw0xwU40
ALL 12 patients with locally advanced rectal cancer had a clinical complete response with no evidence of tumors. No invasive surgery, no radiation, no chemotherapy. This is literally a cure for cancer! https://t.co/2HDfuDaW6D
100% remissie van kanker bereikt bij ALLE patiënten in baanbrekend onderzoek bij Rectale Kanker PD-1 Blockade in Mismatch Repair–Deficient, Locally Advanced Rectal Cancer https://t.co/pkkIMbdFik https://t.co/Nd4oeNSa7Y
@HedgeyeHC PD-1 Blockade in Mismatch Repair–Deficient, Locally Advanced Rectal Cancer | New England Journal of Medicine https://t.co/QHyxAEkfIB
PD-1 Blockade in Mismatch Repair–Deficient, Locally Advanced Rectal Cancer | New England Journal of Medicine https://t.co/zMh5MFuUzK
RT @EliasChandran: dMMR / MSI-H tumors express more neoantigens, making them more immunogenic. Recent trials have shown exquisite sensitivi…
dMMR / MSI-H tumors express more neoantigens, making them more immunogenic. Recent trials have shown exquisite sensitivity of localized dMMR / MSI-H rectal and colon cancer to immune checkpoint inhibitors. https://t.co/LsP8T4hNDs https://t.co/Mea900LDZl
RT @Tamama0306: PD-1 Blockade in Mismatch Repair–Deficient, Locally Advanced Rectal Cancer https://t.co/clCmLkPzWc
RT @Tamama0306: PD-1 Blockade in Mismatch Repair–Deficient, Locally Advanced Rectal Cancer https://t.co/clCmLkPzWc
RT @Tamama0306: PD-1 Blockade in Mismatch Repair–Deficient, Locally Advanced Rectal Cancer https://t.co/clCmLkPzWc
PD-1 Blockade in Mismatch Repair–Deficient, Locally Advanced Rectal Cancer https://t.co/clCmLkPzWc
PD-1 Blockade in Mismatch Repair–Deficient, Locally Advanced Rectal Cancer | New England Journal of Medicine https://t.co/M2tI7CyQB0
Trovata una cura efficace al 100% per il cancro in uno studio clinico Questi pazienti non hanno ricevuto chemio, radioterapia e intervento chirurgico. Ciò che è inquietante è che lo studio è stato pubblicato 2022 e non sembra aver fatto notizia https://t.co/E2ApPCIEWQ https://t.co/sjK0kZs0n4
https://t.co/xLSRurvZyQ
The original source from post below: PD-1 Blockade in Mismatch Repair–Deficient, Locally Advanced Rectal Cancer | New England Journal of Medicine https://t.co/CvciPKxzIE
PD-1 Blockade in Mismatch Repair–Deficient, Locally Advanced Rectal Cancer | New England Journal of Medicine https://t.co/5dHD3mUHoZ
PD-1 Blockade in Mismatch Repair–Deficient, Locally Advanced Rectal Cancer | New England Journal of Medicine https://t.co/MQZomqFiKH
PD-1 Blockade in Mismatch Repair–Deficient, Locally Advanced Rectal Cancer | New England Journal of Medicine https://t.co/1NdhngUv44
PD-1 Blockade in Mismatch Repair–Deficient, Locally Advanced Rectal Cancer | New England Journal of Medicine https://t.co/DsNMK64A56 This is promising. 100% "cure" in clinical trial of 12.
PD-1 Blockade in Mismatch Repair–Deficient, Locally Advanced Rectal Cancer | New England Journal of Medicine https://t.co/mmqZsBpL0P
PD-1 Blockade in Mismatch Repair–Deficient, Locally Advanced Rectal Cancer | New England Journal of Medicine. 100% remission rates in new cancer drug https://t.co/bn8T6K1HFF
PD-1 Blockade in Mismatch Repair–Deficient, Locally Advanced Rectal Cancer | New England Journal of Medicine https://t.co/qQoemaD0Pu
PD-1 Blockade in Mismatch Repair–Deficient, Locally Advanced Rectal Cancer Phase 2, clinical trial. 12 patients, 100% success rate in the treatment group of 6. www.nejm.org/doi/ful... 1/4
@VigilantFox @VPrasadMDMPH here is the study @VPrasadMDMPH https://t.co/VBoEzQuXAx
RT @KearsargeRacing: @VigilantFox @VigilantFox @zerohedge PD-1 Blockade in Mismatch Repair–Deficient, Locally Advanced Rectal Cancer https…
@VigilantFox @VigilantFox @zerohedge PD-1 Blockade in Mismatch Repair–Deficient, Locally Advanced Rectal Cancer https://t.co/z1hHJRb6P2
PD-1 Blockade in Mismatch Repair–Deficient, Locally Advanced Rectal Cancer | New England Journal of Medicine https://t.co/2eqwXwd88A
臨床試驗中發現前所未有的 100% 治癒癌症方法
PD-1 Blockade in Mismatch Repair–Deficient, Locally Advanced Rectal Cancer | New England Journal of Medicine https://t.co/aRMuwUCHxi "All 12 patients (100%; 95% confidence interval, 74 to 100) had a clinical complete response, with no evidence of tumor"
@VigilantFox https://t.co/bfJYwyGKUj
PD-1 Blockade in Mismatch Repair–Deficient, Locally Advanced Rectal Cancer | New England Journal of Medicine https://t.co/f2oeLL84jV
@jwilkstn Yep looks like it: https://t.co/W04WYTEJnM Not very fresh news I guess... but still encouraging! Will have to go digging now and see if there are any newer studies
RT @5_utr: @f2harrell Excellent point! I’m still stunned treatment guidelines were changed for rectal cancer based on an n=12 single arm tr…
@f2harrell Excellent point! I’m still stunned treatment guidelines were changed for rectal cancer based on an n=12 single arm trial; it got NEJM publication and immediately inserted into treatment guidelines
PD-1 Blockade in Mismatch Repair–Deficient, Locally Advanced Rectal Cancer https://t.co/xdMjoBF0Y8 https://t.co/dVsEQgMiEA
@ProtonStorey @DrewMoghanaki @NCCN https://t.co/rCy783BVzk This is the NEJM paper. I am not aware of other relevant data. Is there any other higher quality trial I am missing?
PD-1 Blockade in Mismatch Repair–Deficient, Locally Advanced Rectal Cancer https://t.co/IsqS7xEPxI
・さらに術前ICIは全身的な抗腫瘍免疫の促進に加え、切除の観点でもプラスとなる可能性あり
Un resultat sorprenent i positiu q permetra progressar en el coneixement i tractament del càncer. Ref. Cercek A, Lumish M, et al. PD-1 Blockade in Mismatch Repair-Deficient, Locally Advanced Rectal Cancer. N Engl J Med. 2022;386(25):2363-2376.doi: 10.1056/NEJMoa2201445.
@DrToddLee @NiuSanford And yet we have celebrations in NEJM about n=12 Funded by the drug manufacturer. Why do people respect this journal? https://t.co/TlsqThxyur
RT @Rob__Brierley: Findings in keeping with: -Dostarlimab (#rectalcancer) -https://t.co/klztJwjQpY @NEJM - PICC (#colorectalcancer) -htt…
Findings in keeping with: -Dostarlimab (#rectalcancer) -https://t.co/klztJwjQpY @NEJM - PICC (#colorectalcancer) -https://t.co/2J7MoTcH6I @LancetGastroHep - NICHE (colon cancer) https://t.co/Qh4roh0bnh @NatureMedicine #gitwitter #crcsm #onctwitter
RT @VivekSubbiah: PD-1 Blockade in Mismatch Repair–Deficient, Locally Advanced Rectal Cancer. COMPLETE RESPOSNES in 12/12 patients. Paradig…
RT @VivekSubbiah: PD-1 Blockade in Mismatch Repair–Deficient, Locally Advanced Rectal Cancer. COMPLETE RESPOSNES in 12/12 patients. Paradig…
RT @VivekSubbiah: PD-1 Blockade in Mismatch Repair–Deficient, Locally Advanced Rectal Cancer. COMPLETE RESPOSNES in 12/12 patients. Paradig…
PD-1 Blockade in Mismatch Repair–Deficient, Locally Advanced Rectal Cancer | NEJM https://t.co/3rDd4897ri
RT @VivekSubbiah: PD-1 Blockade in Mismatch Repair–Deficient, Locally Advanced Rectal Cancer. COMPLETE RESPOSNES in 12/12 patients. Paradig…
RT @VivekSubbiah: PD-1 Blockade in Mismatch Repair–Deficient, Locally Advanced Rectal Cancer. COMPLETE RESPOSNES in 12/12 patients. Paradig…
RT @VivekSubbiah: PD-1 Blockade in Mismatch Repair–Deficient, Locally Advanced Rectal Cancer. COMPLETE RESPOSNES in 12/12 patients. Paradig…
RT @VivekSubbiah: PD-1 Blockade in Mismatch Repair–Deficient, Locally Advanced Rectal Cancer. COMPLETE RESPOSNES in 12/12 patients. Paradig…
RT @VivekSubbiah: PD-1 Blockade in Mismatch Repair–Deficient, Locally Advanced Rectal Cancer. COMPLETE RESPOSNES in 12/12 patients. Paradig…
RT @VivekSubbiah: PD-1 Blockade in Mismatch Repair–Deficient, Locally Advanced Rectal Cancer. COMPLETE RESPOSNES in 12/12 patients. Paradig…
PD-1 Blockade in Mismatch Repair–Deficient, Locally Advanced Rectal Cancer. COMPLETE RESPOSNES in 12/12 patients. Paradigm changing study @NEJM @AndreaCercek @Dr_R_Kurzrock https://t.co/oLZQt04a3O https://t.co/kzUcb9aP5q
PD-1 Blockade in Mismatch Repair–Deficient, Locally Advanced Rectal Cancer | NEJM Just read a article in the Times, about this medical test, that led to complete recovery for all tested for rectal cancer. Shouldn’t this be BIG news? https://t.co/6BohucOZlx
@pinnotyo https://t.co/g7T7okRZeV
PD-1 Blockade in Mismatch Repair–Deficient, Locally Advanced Rectal Cancer | NEJM https://t.co/T6p6Wi5Jr1
PD-1 Blockade in Mismatch Repair–Deficient, Locally Advanced Rectal Cancer https://t.co/MH55EIHRmp
12 patients in study rec’d monoclonal antibodies for rectal cancer stage 2 & 3; ALL 12 patients cured. PD-1 Blockade in Mismatch Repair–Deficient, Locally Advanced Rectal Cancer | NEJM https://t.co/jWAHIFtz9m
RT @CGAIGC:
RT @CGAIGC:
RT @CGAIGC:
RT @CGAIGC:
RT @CGAIGC:
RT @CGAIGC:
RT @CGAIGC:
Fascinating research. Monoclonal antibody treatment sent cancer into complete remission in every patient treated. Very promising. PD-1 Blockade in Mismatch Repair–Deficient, Locally Advanced Rectal Cancer | NEJM https://t.co/4u0OfZRxpX
今日の抄読会
@Caroline_Bartma MSI hi and ras+. Or MSI hi and ras- The MSI status has a incredible effect on the tumor immune microenvironment. As seen at ESMO22 and by https://t.co/Mheax8RPM6.
RT @LuisJaimeCastr3: PD-1 Blockade in Mismatch Repair–Deficient, Locally Advanced Rectal Cancer | NEJM https://t.co/MqSPVUFgWH
PD-1 Blockade in Mismatch Repair–Deficient, Locally Advanced Rectal Cancer | NEJM https://t.co/MqSPVUFgWH
RT @ESTRO_RT: #ESTROnewsletter PD-1 Blockade in Mismatch Repair-Deficient, Locally Advanced Rectal Cancer https://t.co/ALR30qAXQA https://t…
RT @ESTRO_RT: #ESTROnewsletter PD-1 Blockade in Mismatch Repair-Deficient, Locally Advanced Rectal Cancer https://t.co/ALR30qAXQA https://t…
#ESTROnewsletter PD-1 Blockade in Mismatch Repair-Deficient, Locally Advanced Rectal Cancer https://t.co/ALR30qAXQA https://t.co/StTYpux0MH
#LynchFactFriday Dostarlimab, a promising new immunotherapy drug in clinical trials, offers great hope for people with #LynchSyndrome. 6 months from treatment 12 people with rectal cancer no longer showed evidence of tumors.
PD-1 Blockade in Mismatch Repair–Deficient, Locally Advanced Rectal Cancer | NEJM https://t.co/PFuxK8iGMq
[本日の抄読会] dMMR(MSI-H)局所進行直腸癌に対する，PD-1阻害薬dostarlimabによる術前治療を検証した第Ⅱ相試験．MSKCCより． https://t.co/8UQx7c5h7i 16名登録され，全員がCR．手術，放射線省略と．selectionがかかった患者集団ではあるが，薬物治療のみで治せる時代が確実に近づいている様相．
Hot off the presses--Dr. Patrick Sullivan summarizes the results from the recently published results on PD-1 blockade in mismatch repair deficient, locally advanced rectal cancer at #DDHO2022 https://t.co/M9ysCROyBF
RT @CGAIGC: We are kicking off July with a #HereditaryGICancer Tweetorial on a hot topic from June, "PD-1 Blockade in Mismatch Repair-Defic…
Stage II-III rectal cancer with complete response to neoadjuvant immunotherapy alone w/ 12 months follow-up is a big win! Saving patients from typical chemoradiation+surgery. Looking forward to seeing the follow-up results to assess duration of response! https://t.co/wdEK54MINF
https://t.co/7ILjrAOP0m
RT @CGAIGC: We are kicking off July with a #HereditaryGICancer Tweetorial on a hot topic from June, "PD-1 Blockade in Mismatch Repair-Defic…
RT @CGAIGC: We are kicking off July with a #HereditaryGICancer Tweetorial on a hot topic from June, "PD-1 Blockade in Mismatch Repair-Defic…
RT @CGAIGC: We are kicking off July with a #HereditaryGICancer Tweetorial on a hot topic from June, "PD-1 Blockade in Mismatch Repair-Defic…
RT @CGAIGC: We are kicking off July with a #HereditaryGICancer Tweetorial on a hot topic from June, "PD-1 Blockade in Mismatch Repair-Defic…
RT @CGAIGC: We are kicking off July with a #HereditaryGICancer Tweetorial on a hot topic from June, "PD-1 Blockade in Mismatch Repair-Defic…
RT @CGAIGC: We are kicking off July with a #HereditaryGICancer Tweetorial on a hot topic from June, "PD-1 Blockade in Mismatch Repair-Defic…
RT @CGAIGC: We are kicking off July with a #HereditaryGICancer Tweetorial on a hot topic from June, "PD-1 Blockade in Mismatch Repair-Defic…
RT @digitalsci: Making news: according to @altmetric, this colorectal #cancer research from @MSKCancerCenter - presented at @ASCO 2022 and…
RT @digitalsci: Making news: according to @altmetric, this colorectal #cancer research from @MSKCancerCenter - presented at @ASCO 2022 and…
RT @digitalsci: Making news: according to @altmetric, this colorectal #cancer research from @MSKCancerCenter - presented at @ASCO 2022 and…
Making news: according to @altmetric, this colorectal #cancer research from @MSKCancerCenter - presented at @ASCO 2022 and published in @NEJM - has attracted the most attention of any non-COVID paper published last month: https://t.co/kguRTvOH6u @AndreaCercek #ASCO2022 https://t.co/QipE6VU8cs
RT @Shine_McShine: 2/ En primer lugar es de agradecer que, para variar, el periodista haya enlazado el artículo del que habla. Es este de a…
早川智先生FBより。論文になったようです。https://t.co/i3EwhlS8K7
RT @francescodamil6: 元論文はこちらからhttps://t.co/HUytS5vLE9
RT @francescodamil6: 元論文はこちらからhttps://t.co/HUytS5vLE9
元論文はこちらからhttps://t.co/HUytS5vLE9
RT @cancer_evolve: COLORECTAL: in a small study (n=12) of microsatellite unstable locally advanced rectal cancer, neoadjuvant PD-1 inhibiti…
RT @cancer_evolve: COLORECTAL: in a small study (n=12) of microsatellite unstable locally advanced rectal cancer, neoadjuvant PD-1 inhibiti…
RT @yukitsugu1963: PD-1 Blockade in Mismatch Repair–Deficient, Locally Advanced Rectal Cancer | NEJM https://t.co/DMiEjxmUz7 投与した１２人全てPET…
PD-1 Blockade in Mismatch Repair–Deficient, Locally Advanced Rectal Cancer | NEJM https://t.co/DMiEjxmUz7 投与した１２人全てPET陰性！多分治癒！ がんの種類の厳密な区別は必要 でもこれはすごいこと https://t.co/vrobDYJRJ2
RT @cancer_evolve: COLORECTAL: in a small study (n=12) of microsatellite unstable locally advanced rectal cancer, neoadjuvant PD-1 inhibiti…
COLORECTAL: in a small study (n=12) of microsatellite unstable locally advanced rectal cancer, neoadjuvant PD-1 inhibition (dostarlimab) delivered 100% CR rate (all PET-negative); no patients have subsequently progressed (follow up 6 - 25 months). https://t.co/QkAQE9udWm
Impressive results. PD-1 Blockade in Mismatch Repair–Deficient, Locally Advanced Rectal Cancer | NEJM https://t.co/y28eOMfb8o
話題のやつ、有料で読めんけど大学でなら読めるんかな https://t.co/fOEOdnC7oK
RT @RajivSarin5: Media Sensation on Rectal Cancers vanishing with Immuno drug Dostarlimab without Surgery/Radiatn/Chemo Its a signal getti…
https://t.co/G3zHxXwBBO
RT @RajivSarin5: Media Sensation on Rectal Cancers vanishing with Immuno drug Dostarlimab without Surgery/Radiatn/Chemo Its a signal getti…
RT @RajivSarin5: Media Sensation on Rectal Cancers vanishing with Immuno drug Dostarlimab without Surgery/Radiatn/Chemo Its a signal getti…
RT @Aiims1742: The rest as they say is history. Kudos for recognizing the importance of a single exceptional responder amidst near universa…
RT @Aiims1742: The rest as they say is history. Kudos for recognizing the importance of a single exceptional responder amidst near universa…
RT @Aiims1742: The rest as they say is history. Kudos for recognizing the importance of a single exceptional responder amidst near universa…
The rest as they say is history. Kudos for recognizing the importance of a single exceptional responder amidst near universal lack of response to aPD-1 monotherapy in #ColorectalCancer. That observation continues to be leveraged in this genetic subset: https://t.co/pgWYbCtTD5
RT @aegastro:
RT @aegastro:
100% complete clinical response with dostarlimab in stage II or III rectal adenocarcinoma. https://t.co/PhJDfc6xQD @NEJM @MSKCancerCenter
RT @aegastro:
RT @RajivSarin5: Media Sensation on Rectal Cancers vanishing with Immuno drug Dostarlimab without Surgery/Radiatn/Chemo Its a signal getti…
https://t.co/gUziWx5U1H
RT @KordastiL: A complete response to PD-1 blockade in all 12 patients with locally advanced rectal cancer! no surgery or chemo is needed a…
PD-1 Blockade in Mismatch Repair-Deficient, Locally Advanced Rectal Cancer - PubMed. El artículo del qu todos hablan. https://t.co/z9KSmJyiGC
RT @RajivSarin5: Media Sensation on Rectal Cancers vanishing with Immuno drug Dostarlimab without Surgery/Radiatn/Chemo Its a signal getti…
@arimtorresa @Sbeah Lo encontreeee https://t.co/waHyxSLEBU
Thank you @WPLGLocal10 for disseminating this very innovative, exciting, and potentially paradigm-shifting #colorectalsurgery #colorectalcancer information from @NEJM https://t.co/IrIVFQmCM7 https://t.co/av37SNmZ0I
АНУ-Д ХОРТ ХАВДРН ЭСРЭГ ТАРИАНЫ ТУРШИЛТАД ОРОЛЦСОН БҮХ ӨВЧТӨН БҮРЭН ЭДГЭРЧЭЭ!АНУд хгдсэн эмнэл зүйн туршилтр достарлимаб хэмх эмн бэлдмэл н туршилтад хамрагдсан өвчтөн бүрн хорт хавдрг амжилттай устгасан бн. https://t.co/uiNW55BV5o ~copy https://t.co/9CuwVbZuM3
RT @RajivSarin5: Media Sensation on Rectal Cancers vanishing with Immuno drug Dostarlimab without Surgery/Radiatn/Chemo Its a signal getti…
RT @RajivSarin5: Media Sensation on Rectal Cancers vanishing with Immuno drug Dostarlimab without Surgery/Radiatn/Chemo Its a signal getti…
@lomo1910 @prbanjade https://t.co/xXJDVpJCwe
RT @moogii0305: АНУ-Д ХОРТ ХАВДРЫН ЭСРЭГ ТАРИАНЫ ТУРШИЛТАД ОРОЛЦСОН БҮХ ӨВЧТӨН БҮРЭН ЭДГЭРЧЭЭ https://t.co/DRBk8gQ5fd https://t.co/DvyEEY7…
RT @moogii0305: АНУ-Д ХОРТ ХАВДРЫН ЭСРЭГ ТАРИАНЫ ТУРШИЛТАД ОРОЛЦСОН БҮХ ӨВЧТӨН БҮРЭН ЭДГЭРЧЭЭ https://t.co/DRBk8gQ5fd https://t.co/DvyEEY7…
АНУ-Д ХОРТ ХАВДРЫН ЭСРЭГ ТАРИАНЫ ТУРШИЛТАД ОРОЛЦСОН БҮХ ӨВЧТӨН БҮРЭН ЭДГЭРЧЭЭ https://t.co/DRBk8gQ5fd https://t.co/DvyEEY7uLu
RT @Shine_McShine: 2/ En primer lugar es de agradecer que, para variar, el periodista haya enlazado el artículo del que habla. Es este de a…
RT @Shine_McShine: 2/ En primer lugar es de agradecer que, para variar, el periodista haya enlazado el artículo del que habla. Es este de a…
ガンの免疫療法の最新論文。PD-1 Blockade in Mismatch Repair–Deficient, Locally Advanced Rectal Cancer | NEJM #SmartNews https://t.co/9xmu8WouGw
RT @RajivSarin5: Media Sensation on Rectal Cancers vanishing with Immuno drug Dostarlimab without Surgery/Radiatn/Chemo Its a signal getti…
RT @Shine_McShine: 2/ En primer lugar es de agradecer que, para variar, el periodista haya enlazado el artículo del que habla. Es este de a…
АНУ-Д ХОРТ ХАВДРЫН ЭСРЭГ ТАРИАНЫ ТУРШИЛТАД ОРОЛЦСОН БҮХ ӨВЧТӨН БҮРЭН ЭДГЭРЧЭЭ https://t.co/ojOGVomUhS АНУ-д хийгдсэн эмнэл зүйн туршилтаар достарлимаб хэмээх эмийн бэлдмэл нь туршилтад хамрагдсан өвчтөн бүрийн хорт хавдрыг амжилттай устгасан байна.
RT @RajivSarin5: Media Sensation on Rectal Cancers vanishing with Immuno drug Dostarlimab without Surgery/Radiatn/Chemo Its a signal getti…
RT @Shine_McShine: 2/ En primer lugar es de agradecer que, para variar, el periodista haya enlazado el artículo del que habla. Es este de a…
RT @RajivSarin5: Media Sensation on Rectal Cancers vanishing with Immuno drug Dostarlimab without Surgery/Radiatn/Chemo Its a signal getti…
RT @Shine_McShine: 2/ En primer lugar es de agradecer que, para variar, el periodista haya enlazado el artículo del que habla. Es este de a…
RT @Shine_McShine: 2/ En primer lugar es de agradecer que, para variar, el periodista haya enlazado el artículo del que habla. Es este de a…
RT @Shine_McShine: 2/ En primer lugar es de agradecer que, para variar, el periodista haya enlazado el artículo del que habla. Es este de a…
RT @Shine_McShine: 2/ En primer lugar es de agradecer que, para variar, el periodista haya enlazado el artículo del que habla. Es este de a…
RT @RajivSarin5: Media Sensation on Rectal Cancers vanishing with Immuno drug Dostarlimab without Surgery/Radiatn/Chemo Its a signal getti…
@gallinetas20 https://t.co/fLQOXYG1le
RT @genetik_muh: Hastaların %20’si belli yan etkiler ile karşılaştı lakin bu yan etkiler kolayca yönetildi. Çalışma henüz küçük bir grup iç…
RT @Shine_McShine: 2/ En primer lugar es de agradecer que, para variar, el periodista haya enlazado el artículo del que habla. Es este de a…
RT @RajivSarin5: Media Sensation on Rectal Cancers vanishing with Immuno drug Dostarlimab without Surgery/Radiatn/Chemo Its a signal getti…
RT @realdocdan: Huge day for #oncology! Phase II study @AndreaCercek et al. pub @NEJM: anti-PD1-monoclonal #antibody treatment w/ dostarlim…
RT @chernyvaya: Першоджерело https://t.co/Bj2hnpx2l7
RT @Bolorshuuder: АНУ-Д ХОРТ ХАВДРЫН ЭСРЭГ ТАРИАНЫ ТУРШИЛТАД ОРОЛЦСОН БҮХ ӨВЧТӨН БҮРЭН ЭДГЭРЧЭЭ https://t.co/keBY0ijnPE АНУ-д хийгдсэн эмнэ…
RT @Shine_McShine: 2/ En primer lugar es de agradecer que, para variar, el periodista haya enlazado el artículo del que habla. Es este de a…
RT @Bolorshuuder: АНУ-Д ХОРТ ХАВДРЫН ЭСРЭГ ТАРИАНЫ ТУРШИЛТАД ОРОЛЦСОН БҮХ ӨВЧТӨН БҮРЭН ЭДГЭРЧЭЭ https://t.co/keBY0ijnPE АНУ-д хийгдсэн эмнэ…
RT @RajivSarin5: Media Sensation on Rectal Cancers vanishing with Immuno drug Dostarlimab without Surgery/Radiatn/Chemo Its a signal getti…
RT @Shine_McShine: 2/ En primer lugar es de agradecer que, para variar, el periodista haya enlazado el artículo del que habla. Es este de a…
RT @Shine_McShine: 2/ En primer lugar es de agradecer que, para variar, el periodista haya enlazado el artículo del que habla. Es este de a…
RT @medical_xpress: Findings from a prospective phase II study with dostarlimab for advanced local rectal #cancer @myesmo @nejm https://t.c…
RT @Shine_McShine: 2/ En primer lugar es de agradecer que, para variar, el periodista haya enlazado el artículo del que habla. Es este de a…
RT @Bolorshuuder: АНУ-Д ХОРТ ХАВДРЫН ЭСРЭГ ТАРИАНЫ ТУРШИЛТАД ОРОЛЦСОН БҮХ ӨВЧТӨН БҮРЭН ЭДГЭРЧЭЭ https://t.co/keBY0ijnPE АНУ-д хийгдсэн эмнэ…
RT @Shine_McShine: 2/ En primer lugar es de agradecer que, para variar, el periodista haya enlazado el artículo del que habla. Es este de a…
RT @Bolorshuuder: АНУ-Д ХОРТ ХАВДРЫН ЭСРЭГ ТАРИАНЫ ТУРШИЛТАД ОРОЛЦСОН БҮХ ӨВЧТӨН БҮРЭН ЭДГЭРЧЭЭ https://t.co/keBY0ijnPE АНУ-д хийгдсэн эмнэ…
RT @Bolorshuuder: АНУ-Д ХОРТ ХАВДРЫН ЭСРЭГ ТАРИАНЫ ТУРШИЛТАД ОРОЛЦСОН БҮХ ӨВЧТӨН БҮРЭН ЭДГЭРЧЭЭ https://t.co/keBY0ijnPE АНУ-д хийгдсэн эмнэ…
RT @Bolorshuuder: АНУ-Д ХОРТ ХАВДРЫН ЭСРЭГ ТАРИАНЫ ТУРШИЛТАД ОРОЛЦСОН БҮХ ӨВЧТӨН БҮРЭН ЭДГЭРЧЭЭ https://t.co/keBY0ijnPE АНУ-д хийгдсэн эмнэ…
АНУ-Д ХОРТ ХАВДРЫН ЭСРЭГ ТАРИАНЫ ТУРШИЛТАД ОРОЛЦСОН БҮХ ӨВЧТӨН БҮРЭН ЭДГЭРЧЭЭ https://t.co/keBY0ijnPE АНУ-д хийгдсэн эмнэл зүйн туршилтаар достарлимаб хэмээх эмийн бэлдмэл нь туршилтад хамрагдсан өвчтөн бүрийн хорт хавдрыг амжилттай устгасан байна.
RT @ascon_miguel: Increible pero cierto!
RT @Shine_McShine: 2/ En primer lugar es de agradecer que, para variar, el periodista haya enlazado el artículo del que habla. Es este de a…
RT @medical_xpress: Findings from a prospective phase II study with dostarlimab for advanced local rectal #cancer @myesmo @nejm https://t.c…
RT @medical_xpress: Findings from a prospective phase II study with dostarlimab for advanced local rectal #cancer @myesmo @nejm https://t.c…
RT @medical_xpress: Findings from a prospective phase II study with dostarlimab for advanced local rectal #cancer @myesmo @nejm https://t.c…
Findings from a prospective phase II study with dostarlimab for advanced local rectal #cancer @myesmo @nejm https://t.co/pZWoEKIBZ0 https://t.co/FMs75P5Z7S
Increible pero cierto!
RT @Shine_McShine: 2/ En primer lugar es de agradecer que, para variar, el periodista haya enlazado el artículo del que habla. Es este de a…
RT @JAX_CKB: Exciting results show all 12 patients with MMR-deficient, locally advanced rectal cancer achieved a complete response to singl…
RT @RajivSarin5: Media Sensation on Rectal Cancers vanishing with Immuno drug Dostarlimab without Surgery/Radiatn/Chemo Its a signal getti…
RT @RajivSarin5: Media Sensation on Rectal Cancers vanishing with Immuno drug Dostarlimab without Surgery/Radiatn/Chemo Its a signal getti…
RT @Shine_McShine: 2/ En primer lugar es de agradecer que, para variar, el periodista haya enlazado el artículo del que habla. Es este de a…
RT @Shine_McShine: 2/ En primer lugar es de agradecer que, para variar, el periodista haya enlazado el artículo del que habla. Es este de a…
RT @Shine_McShine: 2/ En primer lugar es de agradecer que, para variar, el periodista haya enlazado el artículo del que habla. Es este de a…
RT @RajivSarin5: Media Sensation on Rectal Cancers vanishing with Immuno drug Dostarlimab without Surgery/Radiatn/Chemo Its a signal getti…
RT @RajivSarin5: Media Sensation on Rectal Cancers vanishing with Immuno drug Dostarlimab without Surgery/Radiatn/Chemo Its a signal getti…
RT @RajivSarin5: Media Sensation on Rectal Cancers vanishing with Immuno drug Dostarlimab without Surgery/Radiatn/Chemo Its a signal getti…
RT @RajivSarin5: Media Sensation on Rectal Cancers vanishing with Immuno drug Dostarlimab without Surgery/Radiatn/Chemo Its a signal getti…
RT @RajivSarin5: Media Sensation on Rectal Cancers vanishing with Immuno drug Dostarlimab without Surgery/Radiatn/Chemo Its a signal getti…
RT @Shine_McShine: 2/ En primer lugar es de agradecer que, para variar, el periodista haya enlazado el artículo del que habla. Es este de a…
RT @Shine_McShine: 2/ En primer lugar es de agradecer que, para variar, el periodista haya enlazado el artículo del que habla. Es este de a…
@NazologyInfo リツイートは控えるけど...本当なら夢のような出来事だ！ といいつつNEJMでいそいそと原文をあたったりしているあたりもうね...w https://t.co/FnUjuNoFR2
RT @Shine_McShine: 2/ En primer lugar es de agradecer que, para variar, el periodista haya enlazado el artículo del que habla. Es este de a…
2/ En primer lugar es de agradecer que, para variar, el periodista haya enlazado el artículo del que habla. Es este de aquí, aunque or desgracia se encuentra tras un paywall y todavía no está en sci-hub: https://t.co/PClbwP8UXO
Media Sensation on Rectal Cancers vanishing with Immuno drug Dostarlimab without Surgery/Radiatn/Chemo Its a signal getting brighter but 1 among many wins of #CancerResearch that needs unlimited Public support & resources/ facilitation from Govt/Charities https://t.co/sz0DpWBC2v https://t.co/n53DDFJm6i
Hastaların %20’si belli yan etkiler ile karşılaştı lakin bu yan etkiler kolayca yönetildi. Çalışma henüz küçük bir grup içinde yapıldığı için alınacak çok yol var. Tedavinin diğer kanser türlerinde etkili olup olmayacağı araştırılıyor
RT @JAX_CKB: Exciting results show all 12 patients with MMR-deficient, locally advanced rectal cancer achieved a complete response to singl…
RT @pona_igor: @iurevych_iurii @fantichok https://t.co/bC5pY4uYPu
RT @JAX_CKB: Exciting results show all 12 patients with MMR-deficient, locally advanced rectal cancer achieved a complete response to singl…
Cancer drug had 100% success rate The findings are reported in The New England Journal of Medicine.https://t.co/UJzZ5ovtGC #CancerResearch #cancer #US #medicalscience https://t.co/EJVJ0acxio
@Slava__Ukraine_ @bichikota https://t.co/Bj2hnpx2l7
RT @JAX_CKB: Exciting results show all 12 patients with MMR-deficient, locally advanced rectal cancer achieved a complete response to singl…
RT @chernyvaya: Першоджерело https://t.co/Bj2hnpx2l7
Great hope for cancer patients… yet to see the long term and significant number of patients with the results… PD-1 Blockade in Mismatch Repair–Deficient, Locally Advanced Rectal Cancer | NEJM great https://t.co/epN0C0kgg3
Першоджерело https://t.co/Bj2hnpx2l7
@hunk62 @fantichok https://t.co/bC5pY4uYPu
@iurevych_iurii @fantichok https://t.co/bC5pY4uYPu
RT @JAX_CKB: Exciting results show all 12 patients with MMR-deficient, locally advanced rectal cancer achieved a complete response to singl…
Huge day for #oncology! Phase II study @AndreaCercek et al. pub @NEJM: anti-PD1-monoclonal #antibody treatment w/ dostarlimab, results in
RT @JAX_CKB: Exciting results show all 12 patients with MMR-deficient, locally advanced rectal cancer achieved a complete response to singl…
Exciting results show all 12 patients with MMR-deficient, locally advanced rectal cancer achieved a complete response to single-agent PD-1 blockade recently presented at #ASCO22 and published in @NEJM! #PrecisionMedicine #immunotherapy https://t.co/gaW9vrcnTo
https://t.co/c7FRTpRg0H
A complete response to PD-1 blockade in all 12 patients with locally advanced rectal cancer! no surgery or chemo is needed after several months. This is fantastic! https://t.co/lzPN5xh0BR
RT @SheepNoMore7: In einer neuen vielversprechenden Krebsstudie wurden 12 von 12 Patienten erfolgreich geheilt. https://t.co/Va06tccSOb
Dostarlimab, een imuuntherapie van Glaxo [GSK] tegen Endeldarm kanker heeft een 100% succes ratio. Zeker de moeite waard om dit middel in de gaten te houden voor andere vormen van kanker https://t.co/Xj9D1JnRhA https://t.co/k5Kgs2Gqnc
In einer neuen vielversprechenden Krebsstudie wurden 12 von 12 Patienten erfolgreich geheilt. https://t.co/Va06tccSOb
In einer neuen vielversprechenden Krebsstudie wurden 12 von 12 Patienten erfolgreich geheilt. https://t.co/Va06tccSOb
Fascinating new article in NEJM [PMID: 35660797]; reporting that all 12 patients in a Phase 2 study investigating dostarlimab for rectal adenocarcinoma had a clinical complete response - with no evidence of tumour detected! https://t.co/Cd4RjvqFEq #cancer #research #lifescience https://t.co/oyhVyBBkOH
PD-1 Blockade in Mismatch Repair–Deficient, Locally Advanced Rectal Cancer https://t.co/CHj8KbYjlR
Wow! This is big. If this is scalable, its a great news for the society, and all the cancer researchers. PD-1 Blockade in Mismatch Repair-Deficient, Locally Advanced Rectal Cancer https://t.co/uEseZwUKUB
This interesting study published in NEJM suggests that blocking PD-1, using dostarlimab, can cure mismatch Repair-Deficient, Locally Advanced Rectal Cancer. https://t.co/nhcORFnMGM ->Insights into cancer: https://t.co/DL81Ei67OH https://t.co/y5n4G5FKGC https://t.co/Htpbwo6ZES https://t.co/gHP7xzXqWg
This is incredible SubhanaAllah https://t.co/6JEmTcGhMn
RT @AndreaBranda8: Hito científico: cáncer de colon eliminado! https://t.co/ieMJlmIuaL
PD-1 Blockade in Mismatch Repair–Deficient, Locally Advanced Rectal Cancer | NEJM https://t.co/9PjmaK7Xbn
ミスマッチ修復欠損進行肛門癌にチェックポイント阻害剤が著効⁉️ 12例中12例でfull response. 治療開始から１年で化学放射線療法は0例で使用。 PD-1 Blockade in Mismatch Repair-Deficient, Locally Advanced Rectal Cancer - PubMed https://t.co/d1W9S0KLgA
@Jayson_Parker https://t.co/7uBsQgZ9QD
RT @AndreaBranda8: Hito científico: cáncer de colon eliminado! https://t.co/ieMJlmIuaL
Hito científico: cáncer de colon eliminado! https://t.co/ieMJlmIuaL
Πολύ καλά νέα αυτά https://t.co/Sa7rEWBot8
RT @dr_bhushannk: Unheard of - Complete Remission of rectal cancer in every single patient in small drug trial. What an amazing scientific…
Unheard of - Complete Remission of rectal cancer in every single patient in small drug trial. What an amazing scientific achievement! #dostarlimab #scientists #MedTwitter #CancerResearch #clinicaltrials https://t.co/1kQT4ih6U3 https://t.co/4PCu3gJmYz
Awesome! https://t.co/F3mRakpmSb
PD-1 Blockade in Mismatch Repair–Deficient, Locally Advanced Rectal Cancer https://t.co/ZqRdcbOnu4
الي يبغى يستزيد ويقرأ بعض التفاصيل هنا رابط الدراسة ورابط آخر يتكلم عن الدراسة • https://t.co/vgguiddsDe • https://t.co/cSafgnXVC3
¿Abrirá la inmunoterapia más caminos hacia la preservación de órgano en cáncer rectal? La respuesta parece evidente. https://t.co/GcVY1vYVhW
PD-1 Blockade in Mismatch Repair–Deficient, Locally Advanced Rectal Cancer #conquercancer https://www.nejm.org/doi/full/10.1056/NEJMoa2201445
SS
E
S
E
DD
AM
R
D
WF